Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab.
Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab.
复制标题
DOI：
10.1111/1759-7714.14068
复制
发表时间：
2021-08
期刊：
影响因子：
2.9
通讯作者：
Yamaguchi Y
中科院分区：
文献类型：
--
作者：
Mizushina Y;Ohyanagi F;Shiihara J;Nomura M;Ohta H;Oshiro H;Tsubochi H;Kusaka G;Yamaguchi Y
1例52岁男性因既往诊断为原发性梭形细胞癌（pT 4 aN 1 M0，III期B）伴程序性死亡配体1表达（肿瘤比例评分≥95%）且无表皮生长因子受体基因突变和间变性淋巴瘤激酶融合基因而接受左肺切除术。但出现脑转移和胸壁肿瘤复发。考虑到伽玛刀治疗脑转移瘤和联合化疗（紫杉醇、卡铂和贝伐珠单抗）的改善不足，在使用开颅术进行脑肿瘤减容后，开始帕博利珠单抗单药治疗和姑息性放射治疗胸部转移瘤。脑水肿假性进展并伴有体力状态下降后，脑水肿和胸壁转移显着改善;这种效果持续到帕博利珠单抗给药11个周期。肺梭形细胞癌预后差，通常对细胞毒化疗耐药。我们的研究结果表明，免疫检查点抑制剂（ICI）是肺梭形细胞癌的一种新的治疗策略。
A 52‐year‐old man underwent pneumonectomy of the left lung for previously diagnosed primary spindle cell carcinoma (pT4aN1M0, stage III B) with programmed death‐ligand 1 expression (tumor proportion score ≥95%) and without epidermal growth factor receptor gene mutation and anaplastic lymphoma kinase fusion gene. However, brain metastasis and chest wall tumor relapse occurred. Considering insufficient improvement with gamma knife treatment for brain metastasis and combination chemotherapy (paclitaxel, carboplatin, and bevacizumab), pembrolizumab monotherapy and palliative irradiation therapy for chest metastases were started after brain tumor volume reduction using craniotomy. Brain edema and chest wall metastases markedly improved following a pseudoprogression of the brain edema accompanied by a performance status decline; this effect continued until 11 cycles of pembrolizumab administration. Lung spindle cell carcinoma has a poor prognosis and is usually resistant to cytotoxic chemotherapy. Our findings suggest that immune checkpoint inhibitors (ICIs) are a novel therapeutic strategy for lung spindle cell carcinoma.
登录
查看更多内容
影响因子：
2.9
作者：
Melian M;Lorente D;Aparici F;Juan O
通讯作者：
Juan O
DOI：
10.31662/jmaj.2019-0015
发表时间：
2020-01-15
期刊：
JMA journal
影响因子：
--
作者：
Tsurumi K;Kawashima Y;Akahira J;Saito R;Toi Y;Nakamura A;Yamanda S;Kimura Y;Honda Y;Sugawara S
通讯作者：
Sugawara S
影响因子：
51.1
作者：
Goldberg, Sarah B.;Schalper, Kurt A.;Kluger, Harriet M.
通讯作者：
Kluger, Harriet M.
DOI：
10.1016/s1470-2045(15)00088-1
发表时间：
2015-11
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Okada H;Weller M;Huang R;Finocchiaro G;Gilbert MR;Wick W;Ellingson BM;Hashimoto N;Pollack IF;Brandes AA;Franceschi E;Herold-Mende C;Nayak L;Panigrahy A;Pope WB;Prins R;Sampson JH;Wen PY;Reardon DA
通讯作者：
Reardon DA
DOI：
10.1097/jto.0b013e318292be18
发表时间：
2013-06
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Velcheti V;Rimm DL;Schalper KA
通讯作者：
Schalper KA